Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04837339

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
900 (estimated)
Sponsor
Hopital Foch · Academic / Other
Sex
All
Age
15 Years
Healthy volunteers
Not accepted

Summary

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.

Conditions

Interventions

TypeNameDescription
OTHERCollection of biological samplesBlood sample, biopsies sample, hair sample.

Timeline

Start date
2022-03-17
Primary completion
2037-03-01
Completion
2037-03-01
First posted
2021-04-08
Last updated
2022-08-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04837339. Inclusion in this directory is not an endorsement.